RxDoctor Payments Data

Amritpal Anand, MD

Rheumatology · Elgin, ILNPI 1770701716

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 94.8% of the total across 242 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 25 manufacturers reported payments, led by AbbVie at 34.3% of the total. Reporting peaked in 2021 at $1,926 and has fallen 77.4% since, to $435 in 2025.

$5,732in general payments, 2019–2025

Across 242 payments — averaging $23.69 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$2K
  • Amgen$931
  • Johnson & Johnson$610
  • AstraZeneca$325
  • Pacira Therapeutics, Inc.$266
  • UCB, Inc.$241
  • plus $1K from 19 others
$34,597in research payments, 2019–2025

Across 2 payments — averaging $17,299 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Eli Lilly$35K

What the payments were for

  • Consulting fees$200%
  • Food & beverage$5,43295%
  • Education$2805%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$5,732 in reported general payments places this provider in the 75th percentile of 287 rheumatology providers in Illinois.

See all rheumatology providers in Illinois

Medicare billing

Part B allowed, 2024
$336,919
Medicare patients
244
Services billed
22,577

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab15$178,516
Enbrel SureclickEtanercept16$114,784
Xeljanz XrTofacitinib Citrate17$114,125
Taltz AutoinjectorIxekizumab11$76,536
Hydroxychloroquine Sulfate235$8,150
Leflunomide121$7,305
MethotrexateMethotrexate Sodium212$6,407
Mycophenolate Mofetil24$3,302
Celecoxib23$1,856
Allopurinol69$946
Colchicine12$936
Famotidine29$793
Gabapentin40$534
Prednisone77$406
Alendronate Sodium41$349

Paid to pharmacies, not to this prescriber.

Other rheumatology in Elgin

See the full list for Illinois

Where these figures come from

Is this you, or does something look wrong? →